QIAGEN NV to Report Quarterly Earnings on Monday

🌥️Trending News

QIAGEN NV ($NYSE:QGEN) is an international provider of sample and assay technologies that are used to enable molecular diagnostics, applied testing, and academic and pharmaceutical research. On Monday, the company will be releasing their quarterly earnings. This quarterly report is expected to provide more insight into the performance of Qiagen NV and how it is positioned for future growth. Analysts and investors will be closely monitoring the announcement as they look for clues about the company’s financial and operational health.

Additionally, market trends in the healthcare and biotech industries will be taken into consideration when assessing the stock’s performance. If the report surpasses expectations, shares of Qiagen NV could see a boost in value.

Earnings

QIAGEN NV will be reporting their quarterly earnings on Monday. According to the earning report of FY2023 Q2 as of June 30 2021, QIAGEN NV achieved a total revenue of 567.31M USD and a net income of 121.05M USD. These figures represent a 10.0% increase in total revenue and 25.2% increase in net income compared to the same period last year.

Looking back to the last three years, QIAGEN NV’s total revenue has reduced from 567.31M USD to 494.86M USD. Investors and stakeholders will be keenly watching this announcement to understand how the company is performing during these turbulent times.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Qiagen Nv. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Qiagen Nv. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Qiagen Nv. More…

Key Ratios Snapshot

Some of the financial key ratios for Qiagen Nv are shown below. More…

Share Price

On the day of the announcement, QIAGEN NV‘s stock opened at $37.4 and closed at $37.4, down by 0.5% from its previous closing price of 37.5. Investors will be closely monitoring the results of the company’s earnings report to gain a better understanding of how the business is performing and whether it is meeting or surpassing expectations. Analysts will also be looking for insight into the company’s strategy for the future and any potential risks that may be associated with it. Live Quote…

Analysis

As an investor, one of the first questions you’ll ask yourself when looking into a company is: how much money does it have in assets, and how much liability does it need to pay off? GoodWhale has conducted an analysis of QIAGEN NV‘s financials, and have identified that the company is classified as an ‘elephant’ – a type of business that is rich in assets after deducting off liabilities. The analysis also confirmed that QIAGEN NV has a high health score of 9/10 with regard to its cashflows and debt, meaning that it is capable to sustain future operations in times of crisis. In terms of performance, GoodWhale’s Star Chart reveals that QIAGEN NV is strong in asset and profitability, medium in growth, and weak in dividend. QIAGEN NV may be attractive to those looking for a strong asset base, and those looking for a healthy cashflow. The company’s ability to sustain operations in times of crisis could also be attractive to investors looking for a more longterm investment. More…

Peers

In the market for molecular diagnostics, Qiagen NV faces competition from BioMerieux SA, Agilent Technologies Inc, and Diasorin SpA. These companies offer a range of products and services that are similar to Qiagen NV’s offerings.

– BioMerieux SA ($OTCPK:BMXMF)

Found in 1963, BioMérieux is a French multinational corporation that produces medical diagnostic systems. The company is headquartered in Lyon and has over 11,000 employees in 43 countries.

In terms of market cap, BioMérieux is a large company with a market cap of over 10 billion as of 2022. The company’s return on equity is also strong, at 13.56%.

BioMérieux produces medical diagnostic systems that are used in a variety of settings, including hospitals, clinics, and laboratories. The company’s products are used to diagnose a wide range of conditions, including infections, cancer, and cardiovascular disease.

– Agilent Technologies Inc ($NYSE:A)

Agilent Technologies Inc is a leading global provider of scientific instruments, software, services, and solutions. The company serves the life sciences, diagnostics, and applied chemical markets. Agilent has a market cap of $37.28B as of 2022 and a ROE of 19.27%. The company’s products and services are used by customers in a wide range of industries, including academic and government institutions, pharmaceutical and biotechnology companies, and commercial laboratories.

– Diasorin SpA ($LTS:0GZX)

Diasorin SpA is a publicly traded company with a market capitalization of 6.94B as of 2022. The company has a strong return on equity of 17.96%. Diasorin is engaged in the research, development, and manufacture of diagnostic tests for a number of diseases and conditions. The company’s products are sold in over 60 countries worldwide.

Summary

Qiagen NV is a Dutch multinational company that provides sample and assay technologies for molecular diagnostics, and is set to announce their quarterly earnings on Monday. As one of the largest providers of molecular diagnostics in the world, investors can expect to gain insight into the financial health of the company. Analyzing the company’s financial performance can provide investors with an idea of the company’s potential future growth. In particular, investors should pay attention to net sales, operating income, net income, and free cash flow to assess the financial health of Qiagen NV.

Additionally, investors should consider the company’s operating expenses, capital expenditure plans, total debt and cash flow from investing activities. By analyzing these indicators, investors can form an opinion on the company’s ability to generate profits and achieve long-term growth.